Illumina, Inc. $ILMN Stock Holdings Lessened by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH reduced its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 23.8% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 167,869 shares of the life sciences company’s stock after selling 52,543 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Illumina were worth $16,016,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Rise Advisors LLC increased its stake in Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after buying an additional 224 shares during the period. Parkside Financial Bank & Trust boosted its stake in shares of Illumina by 65.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after buying an additional 115 shares during the period. Cullen Frost Bankers Inc. purchased a new position in shares of Illumina during the 2nd quarter valued at $41,000. NewSquare Capital LLC increased its stake in shares of Illumina by 604.9% in the second quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock worth $41,000 after acquiring an additional 369 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its stake in shares of Illumina by 2,936.8% in the first quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock worth $46,000 after acquiring an additional 558 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Illumina

In related news, Director Scott Gottlieb bought 500 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The shares were acquired at an average price of $122.13 per share, with a total value of $61,065.00. Following the completion of the transaction, the director owned 12,523 shares of the company’s stock, valued at $1,529,433.99. The trade was a 4.16% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.17% of the company’s stock.

Illumina Stock Up 1.6%

Illumina stock opened at $121.97 on Wednesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $153.06. The firm has a fifty day moving average price of $103.75 and a two-hundred day moving average price of $96.73. The firm has a market cap of $18.64 billion, a price-to-earnings ratio of 15.44, a P/E/G ratio of 2.34 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the company posted $1.14 earnings per share. The firm’s revenue for the quarter was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ILMN. Barclays lifted their price objective on Illumina from $95.00 to $100.00 and gave the company an “underweight” rating in a research report on Friday, October 31st. Daiwa Capital Markets cut shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 target price for the company. in a research note on Tuesday, August 12th. Royal Bank Of Canada set a $124.00 price target on shares of Illumina in a research note on Tuesday, September 2nd. Robert W. Baird set a $109.00 price objective on shares of Illumina in a research note on Friday, October 31st. Finally, Stephens set a $110.00 price objective on shares of Illumina and gave the stock an “overweight” rating in a report on Monday, August 4th. Five investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, Illumina has an average rating of “Hold” and a consensus target price of $115.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.